Search company, investor...
Oxford Drug Design company logo

Oxford Drug Design

Founded Year



Bridge | Alive

Total Raised


Last Raised

$2.75M | 6 mos ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+10 points in the past 30 days

About Oxford Drug Design

Oxford Drug Design designs and develops small-molecule drugs against cancer, based on differentiated dual core competences. Its validated platform combines pioneering AI and machine learning methods with deep expertise in aminoacyl-tRNA synthetases, accelerating advances in the discovery and development of oncology therapeutics with novel mechanisms of action. It offers a its proprietary AI platform to pharmaceutical and biotechnology companies. Oxford Drug Design was founded in 2001 and is based in Oxford, England.

Headquarters Location

Oxford Centre for Innovation New Road

Oxford, England, OX1 1BY,

United Kingdom

+44 (0) 1865 261 468

Missing: Oxford Drug Design's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Oxford Drug Design's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Oxford Drug Design

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford Drug Design is included in 4 Expert Collections, including Digital Health.


Digital Health

8,838 items

Startups recreating how healthcare is delivered



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Oxford Drug Design Patents

Oxford Drug Design has filed 1 patent.

The 3 most popular patent topics include:

  • EC 6.1.1
  • Enzymes of known structure
  • Inflammations
patents chart

Application Date

Grant Date


Related Topics




Pyridines, Trifluoromethyl compounds, V8SuperTourer drivers, EC 6.1.1, Enzymes of known structure


Application Date


Grant Date



Related Topics

Pyridines, Trifluoromethyl compounds, V8SuperTourer drivers, EC 6.1.1, Enzymes of known structure



Latest Oxford Drug Design News

ODD receives $2.7 million from existing investors and angels ahead of Series A

Jun 1, 2022

Oxford Drug Design Limited (ODD), a biotechnology company with a computational and machine learning platform, has raised $2.7M (£2.2M) in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory and a number of returning angels.

Oxford Drug Design Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxford Drug Design Rank

Oxford Drug Design Frequently Asked Questions (FAQ)

  • When was Oxford Drug Design founded?

    Oxford Drug Design was founded in 2001.

  • Where is Oxford Drug Design's headquarters?

    Oxford Drug Design's headquarters is located at Oxford Centre for Innovation, Oxford.

  • What is Oxford Drug Design's latest funding round?

    Oxford Drug Design's latest funding round is Bridge.

  • How much did Oxford Drug Design raise?

    Oxford Drug Design raised a total of $14.36M.

  • Who are the investors of Oxford Drug Design?

    Investors of Oxford Drug Design include O2h Ventures, ACF Investors, Meltwind, R42, UK Department of Health and Social Care and 6 more.

  • Who are Oxford Drug Design's competitors?

    Competitors of Oxford Drug Design include e-therapeutics, Prosarix, Averica Discovery Services, Peakdale Molecular, CeNeRx BioPharma and 11 more.

Compare Oxford Drug Design to Competitors

MerLion Pharmaceuticals

MerLion Pharmaceuticals focuses on the discovery and development of drug candidates from natural sources. MerLion collaborates with leading pharmaceutical companies, biotechs and research institutes to identify and develop drug leads in a wide range of therapeutic areas.

AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.


AndroScience intends to use its expertise in natural product chemistry to discover compounds that target at different stages of the androgen activation pathway, and to develop lead compounds into new medicines for acne, androgenetic alopecia, wound healing, benign prostatic hyperplasia, prostate cancer and for other androgen or androgen receptor-related disorders.

Pathfinder Pharmaceuticals

Pathfinder Pharma focuses on drug discovery research from invention through clinical proof of concept. They specialize in viral diseases and related cancers.

Nereus Pharmaceuticals

Nereus Pharmaceuticals is a drug discovery and development company pursuing sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize biologically active compounds, the company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.


Glycopep is engaged in the synthesis and development of unique chemicals and resin products to support drug discovery. Glycopep is providing custom synthesis to academic institutions and pharmaceutical/biotech companies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.